Biotechnology holding company, Tozaiholdings (CEO, Moon-ki Jung,  www.tozaiholdings.com), will exhibit its leading platelet rich plasma (PRP) extraction device product line called ‘PROSYS PRP’ at 'KIMES 2012’ the Korea's largest medical equipment and hospital equipment trade show which will be held at COEX, Seoul from Feb. 16~19.

(Photo: The No. 1 PRP concentrator, ‘PROSYS PRP’ )

Tozaiholdings's flagship product 'PROSYS PRP' is well known for its convenience, safety, and accuracy with high medical grade quality that was first launched in 2008 and firmly established itself as Korea's the leading brand of PRP for its excellence.

'PROSYS PRP' is the first and only medical device product that is recognized among other PRP products in Korea for its safety and quality

under systematic quality management system and has cleared all the necessary license requirements to be marketed and exported worldwide. ‘PROSYS PRP’ is currently being exported to more than 20 countries worldwide including United States, South America, Japan, Southeast Asia, Turkey, and Middle East.

The unique differentiating feature of our ‘PROSYS PRP’ from other domestic PRP is at the heart of ‘Buffy Coat’ which is designed to conveniently extract and separate buffy coat directly through a guided tube that maximizes the extraction of highly enriched PRP concentration.

Most existing PRP products use a mixture of plasma and the buffy coat which lowers the concentration rate of platelets and their final PRP concentration averages 1.2 to 2.5 times the baseline, whereas 'PROSYS PRP' shows concentration yields of average of 5-7 fold increase.

Tozaiholdings supplies two types of 'PROSYS PRP', a Single Kit and Dual Kits. Based on the PRP kit type and its usage, centrifugation and PRP extraction method can be vary for aesthetic and skin care, regenerative, pain medicine, sports medicine and other orthopedic applications for its efficacy.

(Photo: The feature of PROSYS PRP product lines)

Tozaiholdings is active in making strategic investment on prominentR&D bio-venture companies in the early stage and provides financing,

management, technology commercialization, marketing support, and by providing total solutions, Tozaiholdings Inc. strives to be the nation's leading 'Bio-holdingcompany’ in professional healthcare solution.

Tozaiholdings’s leading brand 'PROSYS PRP' is the first PRP bio device to be introduced and manufactured in Korea at our own production facilities under stringent quality control and FDA, GMP, CE, ISO9001 approval, and ‘PROSYSPRP’ is being provided for many clinical studies at the University hospitalsand numerous SCI level evidence based research articles are being reported..

Moon-Ki Jung, a president and CEO of Tozaiholdings, said "there would beuncompromised continuous investment for product reliability and safety, and willpromote the excellence of Korea’s medical and healthcare products worldwide and strengthen our brand image as 'PRP = PROSYS'.”

(Photo: Tozaiholdings booth picture at KIMES 2011)

Tozaiholdings is active in making strategic investment on prominent R&D bio-venture companies in the early stage and provides financing, management, technology commercialization, marketing support, and by providing total solutions, Tozaiholdings Inc. strives to be the nation's leading 'Bio-holding company’ in professional healthcare solution.

Tozaiholdings’s leading brand 'PROSYS PRP' is the first PRP bio device to be introduced and manufactured in Korea at our own production facilities under stringent quality control and FDA, GMP, CE, ISO9001 approval, and ‘PROSYS PRP’ is being provided for many clinical studies at the University hospitals and numerous SCI level evidence based research articles are being reported.

Moon-Ki Jung, a president and CEO of Tozaiholdings said "There would be uncompromised continuous investment for product reliability and safety, and will promote the excellence of Korea’s medical and healthcare products worldwide and strengthen our brand image as 'PRP = PROSYS'”